← Eichor
Condition: Gastroenteropancreatic Neuroendocrine Tumor Gep Net Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Gastroenteropancreatic Neuroendocrine Tumor Gep Net

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancr
Phase 3 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT05884255Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT07302100Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT05196087Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
Phase 4 · 19 location(s) · University Hospital, Antwerp · NCT05701241A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-
Phase 2 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT06505395Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionucl
NA · 5 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06256705Spanish Series of Patients Treated With the Radionuclide Lutetium177
Phase N/A · 20 location(s) · Sociedad Española de Medicina Nuclear e Imagen Molecular · NCT04949282Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Phase 1 · 9 location(s) · RayzeBio, Inc. · NCT07165132Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendoc
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT0642779868Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06155318Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06356467Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Phase 3 · 65 location(s) · Novartis Pharmaceuticals · NCT06784752Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for
Phase 1 · 1 location(s) · Stanford University · NCT04609592Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroe
Phase 2 · 39 location(s) · National Cancer Institute (NCI) · NCT05773274Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric P
Phase 1 · 5 location(s) · ITM Solucin GmbH · NCT06441331A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Pro
Phase 2 · 1 location(s) · National Cancer Institute, Naples · NCT04893785Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
Phase N/A · 2 location(s) · Methodist Health System · NCT04090034DCEUS to Assess Treatment Response to PRRT in GEP-NET
NA · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07319416Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GE
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT04086485Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Meta
Phase 2 · 4 location(s) · University Hospital, Bordeaux · NCT04837885Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 17
Phase 3 · 54 location(s) · RayzeBio, Inc. · NCT05477576Observational Study on GEP-and Pulm-NET Treated at FPG
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06402695PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
Phase 3 · 2 location(s) · Tata Memorial Hospital · NCT07185672Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroend
Phase 4 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06016855Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract,
Phase 2 · 4 location(s) · Aadi Bioscience, Inc. · NCT05997056Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Phase 1 · 2 location(s) · Emory University · NCT07150546A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07635316Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Phase 1/Phase 2 · 19 location(s) · Perspective Therapeutics · NCT05636618
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.